Skip to content
RegenCompliance
All articles
Foundational

Telehealth Marketing Compliance: State Licensure, Prescribing Rules, and the Cross-Border Framework Every Telehealth Practice Needs

Telehealth is one of the fastest-growing healthcare categories and one of the most regulatorily complex for marketing. Here's the full overview of the rules that apply across the category.

8 min readBy RegenCompliance Editorial, FDA/FTC compliance desk

Telehealth has grown from a niche delivery mode to a dominant healthcare category in several specialties - mental health, weight loss, primary care, hormone therapy, dermatology. The marketing compliance framework for telehealth combines standard healthcare marketing rules with telehealth-specific considerations: state-by-state licensure, Ryan Haight Act prescribing rules, cross-border marketing rules, and specific state AG enforcement patterns. This post covers the framework.

State licensure and marketing

Telehealth practices must be licensed in the states where their patients are located. For marketing:

  • Marketing to patients in a state where the practice’s providers aren’t licensed is a consumer-protection issue and potentially a licensure violation.
  • Marketing should accurately represent in which states services are available.
  • “Available nationwide” marketing is misleading if the practice isn’t licensed everywhere.
  • State AGs have pursued telehealth practices for marketing to their state residents without appropriate licensure.

Ryan Haight Act and controlled substances

The Ryan Haight Online Pharmacy Consumer Protection Act restricts online prescribing of controlled substances. Telehealth controlled-substance prescribing has been in regulatory flux, with DEA issuing multiple guidance updates. Marketing considerations:

  • Telehealth prescribing of Schedule II-V controlled substances (including ADHD medications, benzodiazepines, buprenorphine for OUD, testosterone, ketamine) faces specific Ryan Haight considerations.
  • Marketing that implies easy access to controlled substances through telehealth has drawn DEA and state board attention.
  • Current DEA rules and flexibilities change; marketing should reflect current framework.

Common telehealth marketing patterns that draw enforcement

Pattern 1: “Skip the doctor visit” framing

Marketing that minimizes the clinical evaluation step has drawn state medical board and state AG attention. Compliant marketing frames the telehealth visit as a legitimate medical encounter, not as an alternative to medical care.

Pattern 2: “24-hour script” speed marketing

Speed-of-prescription marketing has been specifically criticized for implying inadequate clinical evaluation. State medical boards have cited this language pattern in enforcement.

Pattern 3: Asynchronous vs synchronous misrepresentation

Asynchronous (store-and-forward) and synchronous (real-time video) telehealth have different regulatory status in different states. Marketing should accurately represent the actual service model.

Pattern 4: Licensure status implications

Marketing that implies broader licensure than actually held (e.g., “our doctors can treat you anywhere” when they’re licensed in specific states) creates consumer-protection exposure.

Pattern 5: Specialty-implying language

Telehealth specialty marketing (“our dermatologists,” “our psychiatrists”) should accurately reflect actual specialist credentialing, not general practitioner services marketed under specialist framing.

State-specific enforcement focus

Several states have been particularly active on telehealth marketing:

  • Texas. Texas Medical Board on telehealth prescribing practices; Texas AG under DTPA.
  • California.Medical Board of California on supervision and prescribing; AG under B&P 17500.
  • New York. OPMC on prescribing and corporate practice; AG under Executive Law 63(12).
  • Florida. Florida Board of Medicine plus FDUTPA enforcement.

Category-specific telehealth marketing

Mental health telehealth

See mental health practice marketing compliance post. Add telehealth-specific licensure, HIPAA sensitivity, and Ryan Haight considerations for psychiatric prescribing.

Weight loss / GLP-1 telehealth

See weight loss clinic marketing compliance post. Compounded GLP-1 marketing plus telehealth prescribing considerations stack.

Dermatology telehealth

See dermatology marketing compliance post. Add store-and-forward vs synchronous rules, state-specific teledermatology rules.

Hormone therapy telehealth

See hormone therapy marketing compliance post. Add Ryan Haight considerations for testosterone prescribing, state-specific rules on telehealth hormone prescribing.

Primary care telehealth

Standard primary care rules plus telehealth framework. Marketing should accurately represent the scope of services available through telehealth vs in-person.

Compliant telehealth marketing framework

  • Accurate licensure representation.Specific states where services are available, specific service limitations, specific provider credentialing.
  • Clinical evaluation emphasis. Frame telehealth visits as legitimate medical encounters with appropriate evaluation, not as convenience shortcuts.
  • Clear service model description.Synchronous vs asynchronous, what’s included, what requires in-person referral.
  • Specific pricing disclosure.What’s included in quoted pricing, what’s additional.
  • Conservative prescribing marketing.Especially for controlled substances; avoid speed-focused framing.

Frequently asked questions

Can I market telehealth services to patients in states where I'm not licensed?

Generally no. State AGs have pursued practices that marketed to state residents without appropriate licensure. Geographic targeting of marketing should match your licensure.

How do I handle multi-state telehealth practice marketing?

List specific states where services are available. If services vary by state (some services in some states, all in others), accurately represent that variation.

What are current Ryan Haight Act rules?

This is in active regulatory flux. DEA has issued multiple guidance updates. Current rules should be verified with healthcare regulatory counsel familiar with telehealth controlled-substance prescribing.

Are there specific rules on telehealth asynchronous care marketing?

Yes, varying by state. Some states require synchronous evaluation for prescribing; some allow asynchronous. Marketing should accurately reflect the allowed service model in each state served.

What about HIPAA considerations specific to telehealth?

Platform selection (HIPAA-compliant telehealth platforms), patient communication channels, and data security considerations all affect HIPAA posture. Marketing that makes security claims should reflect actual practices.

How do I stay current on telehealth rule changes?

Subscribe to state medical board updates, monitor DEA guidance, track state-specific telehealth rule changes. Healthcare regulatory counsel with telehealth expertise is essential for practices in this category.

Built for this exact problem

Scan your clinic's content before regulators do.

RegenCompliance checks every word of your marketing against live FDA and FTC enforcement data - and rewrites violations automatically. A 30-second scan can save a $50,000–$5M regulatory response.

Apply for betaTry the free demo

Related in the platform

hub

Regulatory glossary

Weekly compliance brief

One email a week. New enforcement actions, rule changes, and tactical fixes. No spam, unsubscribe anytime.

We only send one email per week. No marketing blasts.

Keep reading

FDA Warning Letters at a 25-Year High: What Every Healthcare Practice Needs to Know in 2026

More than 200 FDA warning letters hit healthcare practices in 2024 - the highest volume in a quarter century. Here is what is being flagged, why regenerative medicine and med spas are on the front line, and what a defensible marketing program looks like now.

Read article

How a Single Social Media Post Can Become a Multi-Million-Dollar FTC Settlement

Multi-million-dollar FTC settlements against stem cell and regenerative medicine clinics now routinely start with a single Instagram caption or Facebook testimonial. Here is how that chain actually works - and the four places clinics lose control of it.

Read article

Structure/Function Claims vs. Disease Claims: The One FDA Distinction That Determines Whether Your Marketing Is Legal

One line separates legal marketing from a warning letter: the difference between a structure/function claim and a disease claim. Most practice owners think they know where the line is. They are usually wrong by one or two key phrases.

Read article